Esperion Therapeutics (NASDAQ:ESPR) entered into a settlement agreement with Renata and an affiliate resolving patent litigation concerning proposed generic versions of NEXLETOL and NEXLIZET in the United States.
Esperion Therapeutics (NASDAQ:ESPR), the pharmaceutical company focused on lipid-management therapies, reported total revenue of $168.4 million for the fourth quarter, representing a 144% increase over the same period last year.
Esperion Therapeutics (NASDAQ:ESPR) moved to significantly broaden its cardiovascular portfolio on Tuesday, announcing a deal to acquire privately held Corstasis Therapeutics and its first-of-its-kind nasal spray for heart failure-related edema.
